BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 25974843)

  • 1. Sclerostin antibody preserves the morphology and structure of osteocytes and blocks the severe skeletal deterioration after motor-complete spinal cord injury in rats.
    Qin W; Li X; Peng Y; Harlow LM; Ren Y; Wu Y; Li J; Qin Y; Sun J; Zheng S; Brown T; Feng JQ; Ke HZ; Bauman WA; Cardozo CC
    J Bone Miner Res; 2015 Nov; 30(11):1994-2004. PubMed ID: 25974843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sclerostin Antibody Reverses the Severe Sublesional Bone Loss in Rats After Chronic Spinal Cord Injury.
    Zhao W; Li X; Peng Y; Qin Y; Pan J; Li J; Xu A; Ominsky MS; Cardozo C; Feng JQ; Ke HZ; Bauman WA; Qin W
    Calcif Tissue Int; 2018 Oct; 103(4):443-454. PubMed ID: 29931461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
    Stolina M; Dwyer D; Niu QT; Villasenor KS; Kurimoto P; Grisanti M; Han CY; Liu M; Li X; Ominsky MS; Ke HZ; Kostenuik PJ
    Bone; 2014 Oct; 67():305-13. PubMed ID: 25093263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retention of osteocytic micromorphology by sclerostin antibody in a concurrent ovariectomy and functional disuse model.
    Zhang D; Miranda M; Li X; Han J; Sun Y; Rojas N; He S; Hu M; Lin L; Li X; Ke HZ; Qin YX
    Ann N Y Acad Sci; 2019 Apr; 1442(1):91-103. PubMed ID: 30644553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sclerostin antibody and interval treadmill training effects in a rodent model of glucocorticoid-induced osteopenia.
    Achiou Z; Toumi H; Touvier J; Boudenot A; Uzbekov R; Ominsky MS; Pallu S; Lespessailles E
    Bone; 2015 Dec; 81():691-701. PubMed ID: 26409255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteocytes reflect a pro-inflammatory state following spinal cord injury in a rodent model.
    Metzger CE; Gong S; Aceves M; Bloomfield SA; Hook MA
    Bone; 2019 Mar; 120():465-475. PubMed ID: 30550849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sclerostin inhibition prevents spinal cord injury-induced cancellous bone loss.
    Beggs LA; Ye F; Ghosh P; Beck DT; Conover CF; Balaez A; Miller JR; Phillips EG; Zheng N; Williams AA; Aguirre JI; Wronski TJ; Bose PK; Borst SE; Yarrow JF
    J Bone Miner Res; 2015 Apr; 30(4):681-9. PubMed ID: 25359699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats.
    Taylor S; Ominsky MS; Hu R; Pacheco E; He YD; Brown DL; Aguirre JI; Wronski TJ; Buntich S; Afshari CA; Pyrah I; Nioi P; Boyce RW
    Bone; 2016 Mar; 84():148-159. PubMed ID: 26721737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sclerostin antibody prevented progressive bone loss in combined ovariectomized and concurrent functional disuse.
    Zhang D; Hu M; Chu T; Lin L; Wang J; Li X; Ke HZ; Qin YX
    Bone; 2016 Jun; 87():161-8. PubMed ID: 26868528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms.
    Chandra A; Lin T; Young T; Tong W; Ma X; Tseng WJ; Kramer I; Kneissel M; Levine MA; Zhang Y; Cengel K; Liu XS; Qin L
    J Bone Miner Res; 2017 Feb; 32(2):360-372. PubMed ID: 27635523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats.
    Ominsky MS; Brown DL; Van G; Cordover D; Pacheco E; Frazier E; Cherepow L; Higgins-Garn M; Aguirre JI; Wronski TJ; Stolina M; Zhou L; Pyrah I; Boyce RW
    Bone; 2015 Dec; 81():380-391. PubMed ID: 26261096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scl-Ab reverts pro-osteoclastogenic signalling and resorption in estrogen deficient osteocytes.
    Allison H; Holdsworth G; McNamara LM
    BMC Mol Cell Biol; 2020 Nov; 21(1):78. PubMed ID: 33148174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of pharmacologic sclerostin inhibition or testosterone administration on soleus muscle atrophy in rodents after spinal cord injury.
    Phillips EG; Beggs LA; Ye F; Conover CF; Beck DT; Otzel DM; Ghosh P; Bassit ACF; Borst SE; Yarrow JF
    PLoS One; 2018; 13(3):e0194440. PubMed ID: 29579075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional Profiling of Laser Capture Microdissected Subpopulations of the Osteoblast Lineage Provides Insight Into the Early Response to Sclerostin Antibody in Rats.
    Nioi P; Taylor S; Hu R; Pacheco E; He YD; Hamadeh H; Paszty C; Pyrah I; Ominsky MS; Boyce RW
    J Bone Miner Res; 2015 Aug; 30(8):1457-67. PubMed ID: 25678055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody.
    Ominsky MS; Niu QT; Li C; Li X; Ke HZ
    J Bone Miner Res; 2014 Jun; 29(6):1424-30. PubMed ID: 24967455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of sclerostin antibody plus parathyroid hormone (1-34) on bone formation in ovariectomized rats.
    Wu J; Cai XH; Qin XX; Liu YX
    Z Gerontol Geriatr; 2018 Jul; 51(5):550-556. PubMed ID: 28364259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis.
    Li X; Ominsky MS; Villasenor KS; Niu QT; Asuncion FJ; Xia X; Grisanti M; Wronski TJ; Simonet WS; Ke HZ
    Endocrinology; 2018 Jan; 159(1):260-271. PubMed ID: 29069393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sclerostin antibody stimulates bone regeneration after experimental periodontitis.
    Taut AD; Jin Q; Chung JH; Galindo-Moreno P; Yi ES; Sugai JV; Ke HZ; Liu M; Giannobile WV
    J Bone Miner Res; 2013 Nov; 28(11):2347-56. PubMed ID: 23712325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
    Li X; Ominsky MS; Warmington KS; Morony S; Gong J; Cao J; Gao Y; Shalhoub V; Tipton B; Haldankar R; Chen Q; Winters A; Boone T; Geng Z; Niu QT; Ke HZ; Kostenuik PJ; Simonet WS; Lacey DL; Paszty C
    J Bone Miner Res; 2009 Apr; 24(4):578-88. PubMed ID: 19049336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength of Intact Bones in Adult Male Rats.
    Suen PK; Zhu TY; Chow DH; Huang L; Zheng LZ; Qin L
    Sci Rep; 2015 Oct; 5():15632. PubMed ID: 26494536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.